Dummer, R. http://orcid.org/0000-0002-2279-6906
Gyorki, D. E.
Hyngstrom, J.
Berger, A. C.
Conry, R.
Demidov, L.
Sharma, A.
Treichel, S. A.
Radcliffe, H.
Gorski, K. S.
Anderson, A.
Chan, E.
Faries, M.
Ross, M. I.
Funding for this research was provided by:
Amgen
Article History
Received: 13 January 2021
Accepted: 17 August 2021
First Online: 4 October 2021
Competing interests
: R.D. has intermittent, project-focused consulting and/or advisory relationships with Novartis, Merck Sharp & Dohme (MSD), Bristol-Myers Squibb (BMS), Roche, Amgen, Takeda, Pierre Fabre, Sun Pharma, Sanofi and Catalym outside the submitted work. D.E.G. received travel expenses and an honorarium from Amgen Inc. J.H. is a contracted reviewer for Ebix publishing (but does not deem this to be relevant to the content of the current publication). He also received travel funding from BMS and served on advisory boards for BMS and Nektar. A.C.B. served on the speaker’s bureau for Cardinal Health. R.C. served on the speaker’s bureau for Merck, BMS, Amgen Inc., Novartis, Array and Regeneron-Sanofi. L.D. received research grants from Novartis, consulting fees for MSD, BMS, Novartis and Roche, served on the advisory board for Novartis, and received honoraria from MSD, BMS, Novartis and Roche. E.C., A.S., S.A.T., H.R., A.A. and K.S.G. are employees of and stockholders in Amgen Inc. M.F. received consulting fees from Delcath Systems Inc. and served on the advisory board for Pulse Biosciences and Novartis. M.I.R. received honoraria from Merck and Amgen Inc., served on the advisory board for Merck and Amgen Inc., received research funding from Amgen and Provectus, and travel expenses from Merck, Amgen Inc., Provectus, Novartis and Castle Biosciences.